Bath & Body Works Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Bath & Body Works is set to report its next quarterly results Wednesday, Aug. 26, with analysts projecting EPS of 24 cents (down from 37 cents a year ago) on revenue of $1.50B (vs. $1.55B last year). The stock recently fell 8.3% to $17.58, while analyst views are mixed: JPM upgraded/raised its Neutral PT to $24, Citi upgraded to Buy with a $25 PT, and Goldman cut to Sell with a $19 PT.

Analysis

BBWI is a classic low-expectation setup where the first-order move will be driven less by EPS and more by whether management can prove the category still supports price/mix without escalating markdowns. With the stock already down sharply into the print, the market is telling us the real variable is margin durability, not a slight revenue miss; a clean beat without guide-up is probably not enough to re-rate the name. The 20-cent quarterly dividend is also important: it leaves limited cushion if cash generation slips, so the payout is now a credibility test as much as a capital-return signal.

Second-order, a weak read-through should pressure other discretionary names tied to impulse gifting and replenishment, especially broader retail baskets like XRT and mall-linked traffic proxies. If BBWI has to defend volume with promotions, that can actually hand share to trade-down channels over the next 1-3 months, including TGT and WMT, while premium beauty names with stronger loyalty economics should be less exposed. The key structural issue over 6-18 months is brand relevance: mature fragrance/body-care concepts can hold up for a few quarters, but once promo intensity rises, multiple compression tends to be persistent.

The contrarian view is that consensus may be over-assigning structural decay to what could still be a cyclical/seasonal slowdown. If management shows stable comps and credible free-cash-flow coverage of the dividend, the stock can squeeze because positioning is already defensive; but absent a guide change, upside is likely capped near the analyst target band rather than a true rerating.

Key Decisions for Investors

• No pre-earnings directional equity position: the risk/reward is poor after an 8% selloff, and the catalyst is guide quality rather than the headline EPS print.
• If the company confirms dividend coverage and gross margin stability, consider a post-print long via BBWI Nov $18/$22 call spread only on a hold above the pre-earnings low; target a squeeze toward $22-$24, stop if the stock loses $17.
• If revenue/margin guidance disappoints, short BBWI vs long XRT for a 1-3 month relative-value trade; this isolates company-specific underperformance while avoiding a pure beta bet.
• Watch the dividend/FCF relationship closely: if commentary implies payout coverage deteriorates or inventory needs rise, treat that as a warning that the 20-cent dividend becomes the next downgrade catalyst.
• Falsifier: a post-earnings close back above the pre-drop level with no guide-down would invalidate the bearish read-through and argue for covering shorts into strength.